SBIR Phase I: Development of a Burn Care Therapy to Prevent Fibrotic Pathologies

NSF Award Search · 01002526DB NSF RESEARCH & RELATED ACTIVIT · $304,984 · view on nsf.gov ↗

Abstract

The broader impact/commercial potential of this small business innovation research (SBIR) Phase I project lies in its potential to transform outcomes for US burn injury survivors; a population burdened by disfigurement, physical limitation, and long-term psychological impacts. While current treatments focus primarily on survival, many patients face permanent reductions in quality of life due to scarring and contractures. This project aims to develop a novel burn care system that actively manages serious burn wounds to reduce scarring and provide better patient outcomes. If successful, the technology could reduce long-term complications, support social reintegration, enable return to work, and enhance quality of life. The economic burden on US health systems is also significant: the average cost of care for a serious burn injury requiring hospitalization exceeds $250,000 and may extend for months or even years. Globally, medical systems pay over $2.6 billion annually on the care and rehabilitation of individuals with serious burns. This project addresses a critical unmet need by aiming to improve patient healing outcomes, and as a consequence will also reduce the need for secondary surgical revision and therapy, thereby decreasing the cost burden on health systems across the country. This Small Business Innovation Research (SBIR) Phase I Project seeks to validate a technology that integrates a three-part sequence of topical anti-scarring therapeutics with a purpose-built dr

Key facts

NSF award ID
2528240
Awardee
TREYSTA MEDICAL TECHNOLOGIES INC (FL)
SAM.gov UEI
EXU1BZHZVFJ9
PI
Marcelo Buzzi
Primary program
01002526DB NSF RESEARCH & RELATED ACTIVIT
All programs
BIOMEDICAL ENG AND DIAGNOSTICS
Estimated total
$304,984
Funds obligated
$304,984
Transaction type
Standard Grant
Period
10/01/2025 → 09/30/2026